Primary |
Product Used For Unknown Indication |
39.1% |
Haematopoietic Stem Cell Mobilisation |
15.8% |
Acute Myeloid Leukaemia |
14.3% |
Drug Use For Unknown Indication |
4.4% |
Prophylaxis |
3.7% |
Myelodysplastic Syndrome |
2.9% |
Multiple Myeloma |
2.6% |
Bone Marrow Conditioning Regimen |
2.2% |
Hypertension |
1.9% |
Nausea |
1.9% |
Pain |
1.8% |
Acute Lymphocytic Leukaemia |
1.5% |
Chronic Lymphocytic Leukaemia |
1.3% |
Non-hodgkin's Lymphoma |
1.2% |
Infection Prophylaxis |
1.0% |
Premedication |
1.0% |
Prophylaxis Of Nausea And Vomiting |
0.9% |
Lymphoma |
0.9% |
Acute Myeloid Leukaemia Recurrent |
0.8% |
Antifungal Prophylaxis |
0.8% |
|
Thrombocytopenia |
10.3% |
Sepsis |
8.7% |
Death |
6.5% |
Febrile Neutropenia |
6.5% |
Pyrexia |
6.5% |
Nausea |
6.0% |
Acute Myeloid Leukaemia |
4.9% |
Vomiting |
4.9% |
Deep Vein Thrombosis |
4.3% |
White Blood Cell Count Decreased |
4.3% |
Hypersensitivity |
3.8% |
Infection |
3.8% |
Interstitial Lung Disease |
3.8% |
Metastases To Central Nervous System |
3.8% |
Myocardial Infarction |
3.8% |
Pancytopenia |
3.8% |
Plasmacytoma |
3.8% |
Therapeutic Response Decreased |
3.8% |
Diarrhoea |
3.3% |
Neutropenia |
3.3% |
|
Secondary |
Product Used For Unknown Indication |
32.9% |
Acute Myeloid Leukaemia |
13.4% |
Haematopoietic Stem Cell Mobilisation |
11.6% |
Drug Use For Unknown Indication |
5.7% |
Infection Prophylaxis |
5.0% |
Prophylaxis |
4.9% |
Premedication |
4.0% |
Multiple Myeloma |
3.1% |
Mineral Supplementation |
2.3% |
Dry Eye |
2.2% |
Bone Marrow Conditioning Regimen |
2.1% |
Nausea |
2.1% |
Myelodysplastic Syndrome |
1.8% |
Diarrhoea |
1.6% |
Hypertension |
1.3% |
Prophylaxis Against Graft Versus Host Disease |
1.3% |
Pain |
1.2% |
Constipation |
1.2% |
Gastrooesophageal Reflux Disease |
1.2% |
Non-hodgkin's Lymphoma |
1.1% |
|
Hyperbilirubinaemia |
17.1% |
Urinary Tract Infection Enterococcal |
11.4% |
Nausea |
7.0% |
Therapeutic Response Decreased |
6.3% |
Influenza |
5.1% |
Pyrexia |
5.1% |
Sepsis |
5.1% |
Thrombocytopenia |
5.1% |
Acute Myeloid Leukaemia |
4.4% |
Neutropenia |
4.4% |
Pneumothorax |
3.8% |
Diarrhoea |
3.2% |
Pancytopenia |
3.2% |
Pneumonia |
3.2% |
Septic Shock |
3.2% |
Blood Stem Cell Harvest Failure |
2.5% |
Cellulitis |
2.5% |
Infection |
2.5% |
Respiratory Failure |
2.5% |
Upper Respiratory Tract Infection |
2.5% |
|
Concomitant |
Product Used For Unknown Indication |
35.1% |
Drug Use For Unknown Indication |
28.6% |
Acute Myeloid Leukaemia |
7.1% |
Diffuse Large B-cell Lymphoma |
6.0% |
Haematopoietic Stem Cell Mobilisation |
5.4% |
Bone Marrow Conditioning Regimen |
2.4% |
Chronic Myeloid Leukaemia |
2.4% |
Chemotherapy |
2.1% |
Antifungal Treatment |
1.2% |
Mineral Supplementation |
1.2% |
Plasma Cell Myeloma |
1.2% |
Premedication |
1.2% |
Stem Cell Transplant |
1.2% |
Stomatitis |
1.2% |
Pain |
0.9% |
Affective Disorder |
0.6% |
Antiviral Treatment |
0.6% |
Anxiety |
0.6% |
Blood Pressure Abnormal |
0.6% |
Central Venous Catheterisation |
0.6% |
|
Venoocclusive Disease |
24.0% |
Thrombocytopenia |
16.0% |
Drug Ineffective |
8.0% |
Acute Graft Versus Host Disease |
4.0% |
Blood Immunoglobulin A Increased |
4.0% |
Diarrhoea |
4.0% |
Dizziness Postural |
4.0% |
Escherichia Sepsis |
4.0% |
Pallor |
4.0% |
Plasma Cell Myeloma |
4.0% |
Proctitis |
4.0% |
Renal Failure |
4.0% |
Renal Failure Acute |
4.0% |
Stem Cell Transplant |
4.0% |
Ventricular Tachycardia |
4.0% |
Viral Haemorrhagic Cystitis |
4.0% |
|